EP0830134A1 - Zusammensetzungen zur behandlung und vorbeugung von magen-darmstörungen welche wismut enthalten - Google Patents

Zusammensetzungen zur behandlung und vorbeugung von magen-darmstörungen welche wismut enthalten

Info

Publication number
EP0830134A1
EP0830134A1 EP96915593A EP96915593A EP0830134A1 EP 0830134 A1 EP0830134 A1 EP 0830134A1 EP 96915593 A EP96915593 A EP 96915593A EP 96915593 A EP96915593 A EP 96915593A EP 0830134 A1 EP0830134 A1 EP 0830134A1
Authority
EP
European Patent Office
Prior art keywords
bismuth
milligrams
per day
subject
parasitic protozoa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96915593A
Other languages
English (en)
French (fr)
Inventor
Jamesina Anne Fitzgerald
Joshua Lederberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of EP0830134A1 publication Critical patent/EP0830134A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/29—Antimony or bismuth compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • an object of the present invention is to provide a safe and effective method of preventing and/or treating gastrointestinal disorders caused or mediated by parasitic protozoa.
  • a further object of the invention is to provide such a method comprising the administration of bismuth.
  • the present invention relates to a method for treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by one or more parasitic protozoa comprising administering to the subject from about 50 milligrams to about 5000 milligrams of bismuth, per day, for from about 1 to 56 days.
  • the present invention also relates to a method for prevention in a human or lower animal of a gastrointestinal disorder caused or mediated by one or more parasitic protozoa comprising administering to the subject from about 50 milligrams to about 5000 milligrams of bismuth, per day, for from about 1 to 28 days.
  • the methods of the present invention comprise the prevention and/or treatment of gastrointestinal disorder caused or mediated by one or more parasitic protozoa. Such gastrointestinal disorders are prevented and/or treated by the administration of bismuth.
  • the components of the present invention are more fully defined below.
  • gastrointestinal disorder encompasses any infection, disease or other disorder of body, typically of the upper and/or lower gastrointestinal tract, caused or mediated by one or more parasitic protozoa.
  • disorders include one or more of the following conditions: diarrhea, abdominal pain and/or cramping, flatulence, nausea, abdominal distention, fever, constipation, blood, mucus and/or pus present in feces, vomiting, gastroenteritis, weight loss, anorexia, malaise, and any other condition commonly associated with infection by parasitic protozoa.
  • gastrointestinal disorder also includes any condition commonly associated with protozoa infection in immunocompromised subjects and children, including but not limited to, acute diarrhea, dehydration, electrolyte imbalance, colitis, and fatal necrosis of the intestine.
  • Parasitic Protozoa any condition commonly associated with protozoa infection in immunocompromised subjects and children, including but not limited to, acute diarrhea, dehydration, electrolyte imbalance, colitis, and fatal necrosis of the intestine.
  • Protozoa are unicellular, eucaryotic organisms which contain a nucleus, or nuclei, and cytoplasm. Four groups of Protozoa contain parasites which are contemplated in the present invention. These organisms are fully described in Zinsser Microbiology. 20th Edition, 1163- 1173, (1992) and T. L. Kuhls, M.D., "Protozoal Infections of the Intestinal Tract in Children", Advances In Pediatric Infectious Diseases, vol. 8, 177- 202, (1993), both of which are incorporated herein by reference.
  • parasitic protozoa refers to Protozoa of the phlya Sarcomastigophora such as Entamoeba, Giardia, Dientamoeba, and Blastocystis; Ciliophora such as Balantidium; Apicomplexa such as Isospora and Cryptospo dium; and Microspora such as Enterocytozoon.
  • Preferred parasitic protozoa are Entamoeba, Cryptospo ⁇ dium, Giardia, Isospora, and combinations thereof. Most preferred parasitic protozoa are Entamoeba, Cryptospo ⁇ dium, Giardia, and combinations thereof.
  • Diagnosis of gastrointestinal disorders caused or mediated by parasitic protozoa may be accomplished by any method commonly used in the medical community. Such methods are fully described in Zinsser Microbiology, and T.L. Kuhls, M.D. "Protozoal Infections of the Intestinal Tract in Children", as referenced above. Bismuth
  • the methods of treatment and/or prevention in the present invention involve administration of bismuth.
  • the quantity of bismuth is by weight of elemental bismuth.
  • bismuth may be administered in an amount of from about 50 milligrams to about 5000 milligrams, and preferably from about 50 milligrams to about 2500 milligrams, per day, for from about 1 to about 56 days, preferably for from about 2 to about 28 days, and most preferably for from about 7 to about 21 days.
  • bismuth may be administered in an amount of from about 50 milligrams to about 5000 milligrams, and preferably from about 50 milligrams to about 2500 milligrams, per day, for from about 1 to about 21 days, and preferably for from about 1 to about 14 days.
  • bismuth may be administered prior to potential exposure to parasitic protozoa.
  • Such administration of bismuth may vary depending on the likelihood of parasitic protozoa exposure and condition of the subject and may be commenced at any time deemed beneficial by the medical community including from about 1 to about 7 days, from about 2 to about 5 days, and from about 3 to about 4 days, prior to potential exposure.
  • bismuth may be in the form of a pharmaceutically-acceptable salt or may be in the form of an organic complex which contains bismuth as an active ingredient.
  • organic complexes include 2,2'-spirobi[1,3,2-benzodoxabismole].
  • bismuth is administered in the present methods as a pharmaceutically- acceptable salt.
  • Such bismuth salts include bismuth aluminate, bismuth subcarbonate, bismuth subcitrate, bismuth citrate, tripotassium dicitrato bismuthate, bismuth subgalate, bismuth subnitrate, bismuth tartrate, bismuth subsalicylate, and mixtures thereof.
  • Bismuth citrate, bismuth subcitrate, tripotassium dicitrato bismuthate, bismuth tartrate, bismuth subsalicylate, and mixtures thereof are preferred bismuth salts for use in this invention.
  • the bismuth useful herein may be administered alone, or in combination with other pharmaceutically-acceptable components in a bismuth-containing composition.
  • a variety of such compositions containing bismuth salts are commercially available.
  • compositions include DeNol, containing tripotassium dicitrato bismuthate (by Brocades); Bislumina, containing bismuth aluminate (by Mazuelos); Roter, containing bismuth subnitrate (by Roterpharma); Devrom®, containing bismuth subgallate (by The Parthenon Co., Inc.); and Pepto-Bismol®, containing bismuth subsalicylate (by The Procter & Gamble Company).
  • administering refers to any method which, in sound medical practice delivers the compounds or compositions used in this invention to the subject to be treated in such a manner so as to be effective in the treatment of the gastrointestinal disorder.
  • the bismuth is administered orally.
  • a human subject, suffering from severe diarrhea, is treated by a method of the present invention.
  • Fecal samples are taken from the subject and analyzed for the presence of intestinal parasites, including organism eggs, cysts, sporozoites, etc.
  • Clinical parasitology specimens reveal the presence of Cryptospo ⁇ dium parvum.
  • the subject is then treated by administering a composition containing bismuth subsalicylate, sold by The Procter & Gamble Company under the name "Pepto-Bismol®".
  • the composition in liquid form, is administered four times daily in equal doses delivering approximately 2500 milligrams of bismuth per day, for 21 days. Thereafter, fecal samples from the subject are analyzed again, finding no trace of parasitic infection.
  • a three-year-old child with diabetes and in a day care center is suffering from chronic diarrhea, and abdominal distention.
  • Analysis of fecal specimens shows the presence of Giardia lamblia.
  • the infection is diagnosed and treated by orally administering approximately 400 milligrams of bismuth in the form of bismuth subcitrate ("DeNol", sold by Brocades), in four equal doses daily, for about 28 days. Thereafter, fecal samples from the subject are analyzed again, finding no trace of parasitic infection.
  • a Peace Corps volunteer preparing to travel to a developing country with sub-standard sanitation and water purification systems has a fecal sample clinically analyzed for the presence of Giardia lamblia, Cryptospo ⁇ dium parvum, and Entamoeba histolytica. Clinical results show no evidence of the parasites.
  • the subject is given approximately 1200 milligrams of bismuth, (administered as bismuth subsalicylate in the composition Pepto-Bismol®, sold by The Procter & Gamble Company), in four equal doses daily, for about 21 days.
  • the subject Upon return to the U.S., approximately 30 days after the initial clinical analysis, the subject remains asymptomatic. Fecal samples from the subject are analyzed and no evidence of parasitic infection is found.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP96915593A 1995-05-09 1996-05-08 Zusammensetzungen zur behandlung und vorbeugung von magen-darmstörungen welche wismut enthalten Withdrawn EP0830134A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43785595A 1995-05-09 1995-05-09
US437855 1995-05-09
PCT/US1996/006488 WO1996035435A1 (en) 1995-05-09 1996-05-08 Compositions containing bismuth, for the treatment and prevention of gastrointestinal disorders

Publications (1)

Publication Number Publication Date
EP0830134A1 true EP0830134A1 (de) 1998-03-25

Family

ID=23738205

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96915593A Withdrawn EP0830134A1 (de) 1995-05-09 1996-05-08 Zusammensetzungen zur behandlung und vorbeugung von magen-darmstörungen welche wismut enthalten

Country Status (5)

Country Link
EP (1) EP0830134A1 (de)
JP (1) JPH11504939A (de)
AU (1) AU5733596A (de)
CA (1) CA2219771A1 (de)
WO (1) WO1996035435A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60043886D1 (de) 1999-05-27 2010-04-08 Euro Celtique Sa Formulierungen mit povidon-iod zur behandlung von wunden
US7300667B1 (en) 1999-05-27 2007-11-27 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR119F (de) * 1963-10-26
US4514421A (en) * 1979-08-30 1985-04-30 Herschler R J Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it
US4940695A (en) * 1987-12-10 1990-07-10 The Procter & Gamble Company Bismuth-containing pharmaceutical compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9635435A1 *

Also Published As

Publication number Publication date
AU5733596A (en) 1996-11-29
CA2219771A1 (en) 1996-11-14
JPH11504939A (ja) 1999-05-11
WO1996035435A1 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
Van Asbeck et al. Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload.
Gorsky et al. Metabolic balance of aluminum studied in six men.
Santini Jr et al. The xylose tolerance test with a five-gram dose
DE3619733A1 (de) Mittel zur behandlung von magen-darm-stoerungen
Sidbury Jr et al. Effect of chelating agent on urinary lead excretion. Comparison of oral and intravenous administration
de Vries et al. Inherited uric acid lithiasis
Teisinger et al. The value of mobilization of lead by calcium ethylene-diamine-tetra-acetate in the diagnosis of lead poisoning
Goodwin et al. Clinical trials with bephenium hydroxynaphthoate against hookworm in Ceylon
Williams et al. Further studies of the absorption, distribution, and elimination of thiouracil
Woodruff et al. Clinical trials with entamide furoate and related compounds: I. In a non-tropical environment
EP0830134A1 (de) Zusammensetzungen zur behandlung und vorbeugung von magen-darmstörungen welche wismut enthalten
Schillinger et al. The toxic effect of intravenous application of the trypanocide isometamidium (Samorin®)
Sawyer STUDIES OF ACID PRODUCTION. II. THE MINERAL LOSS DURING ACIDOSIS.* BY MARGARET SAWYER, L. BAUMANN, AND F. STEVENS.
Gongwer et al. The effects of daily bathing of neonatal rhesus monkeys with an antimicrobial skin cleanser containing chlorhexidine gluconate
Aub et al. Recent investigations of absorption and excretion of lead in the organism
WO1996035436A1 (en) Compositions comprising bismuth and one or more antimicrobials, for the treatment and prevention of gastrointestinal disorders
Linakis et al. Use of sodium polystyrene sulfonate for reduction of plasma lithium concentrations after chronic lithium dosing in mice
WOODS et al. Cutaneous porphyria with porphobilinogenuria: A review and report of a case treated by chelation
Kiser et al. Clinical evaluation of RO 4-2130, a new sulfonamide
CA2239422C (en) Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders
Ginsberg et al. African sleeping sickness presenting in an American emergency department
EP0865287B1 (de) Bismut enthaltende zusammensetzungen zur verhütung und behandlung gastrointestinaler beschwerden
Hitman et al. The treatment of urinary schistosomiasis in Kenya and Nigeria with tris (p-aminophenyl) carbonium pamoate
Mellor et al. Effects of antibiotic treatment on the composition of sheep foetal fluids
Life METABOLISM AND PHARMACODYNAMICS OF CUPRIC COPPER IN THE GOLDFISH (CARASSIUS AURATUS)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20000824

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010305